{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-042231","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-04-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.782228+00:00","generated_at":"2026-06-04T03:41:33.691378+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kiniksa plans Phase 2b trial of abiprubart in Sjogren's Disease; reports RA Cohort 4 data","bullets":["Phase 2b trial in Sjogren's Disease to initiate 2H 2024; 201 patients, 24-week placebo-controlled, primary endpoint ESSDAI.","Cohort 4 RA data: abiprubart 400 mg SC monthly showed DAS28-CRP LS mean difference -0.58 vs placebo (p=0.109, not significant).","Statistically significant ~40% reduction in Rheumatoid Factor in Cohort 4 (p=0.0003); pooled analysis DAS28-CRP diff -0.52 (nominal p=0.010).","Abiprubart development in Sjogren's fully funded through Phase 3; company expects to remain cash flow positive annually."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-042231","json":"https://secwatch.observer/filing/0001104659-24-042231.json","markdown":"https://secwatch.observer/filing/0001104659-24-042231.md","text":"https://secwatch.observer/filing/0001104659-24-042231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924042231/0001104659-24-042231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924042231/tm249997d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T03:41:33.691378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}